Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc.
Bullboard Posts
User Avatar Image
(73)
•••
Comment by greaterfoolFredon Oct 29, 2018 1:45pm
95 Views
Post# 28888671

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Licensing Agreement w/Prothena-USD$1M Upfront+$33M potential

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Licensing Agreement w/Prothena-USD$1M Upfront+$33M potentialThe only option mentioned in the news release is the option to use XB3 with three other compounds. So $33M must be for complete development of four compounds.  But remember that this is a 'first' deal.  The price for deals will only go up from here.
Fred
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities